Vistin Pharma ASA (VISTN) - Total Liabilities

Latest as of March 2026: Nkr103.25 Million NOK ≈ $10.87 Million USD

Based on the latest financial reports, Vistin Pharma ASA (VISTN) has total liabilities worth Nkr103.25 Million NOK (≈ $10.87 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Vistin Pharma ASA liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Vistin Pharma ASA - Total Liabilities Trend (2016–2025)

This chart illustrates how Vistin Pharma ASA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see VISTN total assets.

Vistin Pharma ASA Competitors by Total Liabilities

The table below lists competitors of Vistin Pharma ASA ranked by their total liabilities.

Company	Country	Total Liabilities
Concorde International Group Ltd Class A Ordinary Shares NASDAQ:CIGL	USA	$7.57 Million
Katmerciler Arac Ustu Ekipman Sanayi ve Ticaret AS IS:KATMR	Turkey	TL4.66 Billion
Townsquare Media Inc NYSE:TSQ	USA	$583.33 Million
Yirendai Ltd NYSE:YRD	USA	$5.11 Billion
KUYA SILVER CORP. F:6MR1	Germany	€3.84 Million
IFB Agro Industries Limited NSE:IFBAGRO	India	Rs2.87 Billion
Hasen-Immobilien AG STU:ABHA	Germany	€83.22 Million
Banco Santander Río S.A BA:BRIO	Argentina	AR$19.89 Trillion

Liability Composition Analysis (2016–2025)

This chart breaks down Vistin Pharma ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See VISTN net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.96	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.29	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.23	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vistin Pharma ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vistin Pharma ASA (2016–2025)

The table below shows the annual total liabilities of Vistin Pharma ASA from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	Nkr110.62 Million ≈ $11.64 Million	+46.68%
2024-12-31	Nkr75.42 Million ≈ $7.94 Million	-6.46%
2023-12-31	Nkr80.63 Million ≈ $8.48 Million	-39.81%
2022-12-31	Nkr133.95 Million ≈ $14.10 Million	+133.93%
2021-12-31	Nkr57.26 Million ≈ $6.03 Million	+15.65%
2020-12-31	Nkr49.51 Million ≈ $5.21 Million	-45.45%
2019-12-31	Nkr90.77 Million ≈ $9.55 Million	-39.97%
2018-12-31	Nkr151.21 Million ≈ $15.91 Million	+35.50%
2017-12-31	Nkr111.59 Million ≈ $11.74 Million	+20.11%
2016-12-31	Nkr92.91 Million ≈ $9.78 Million	--

About Vistin Pharma ASA

OL:VISTN Norway Drug Manufacturers - Specialty & Generic

Market Cap

$87.26 Million

Nkr829.24 Million NOK

Market Cap Rank

#19780 Global

#176 in Norway

Share Price

Nkr18.70

Change (1 day)

-1.58%

52-Week Range

Nkr18.70 - Nkr23.70

All Time High

Nkr28.06